BLFSHIGH SIGNALFINANCIAL10-K

BioLife Solutions substantially narrowed losses and reduced debt by 69% despite a 31% revenue decline, while cash position dropped significantly to $33M from $95M.

The dramatic improvement in net losses combined with substantial debt reduction suggests successful cost management and operational restructuring, though the revenue decline and cash burn raise questions about growth trajectory. The company appears to be prioritizing financial stability over growth in the near term, which could signal either strategic repositioning or market challenges.

Comparing 2026-02-26 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

BioLife Solutions showed mixed but notable financial changes, with losses narrowing substantially from $20.2M to $4.6M while revenue declined 31% to $6.2M and gross profit grew 24% to $62.1M. The balance sheet strengthened through debt reduction from $15.9M to $5.0M and overall liability reduction, though cash reserves fell significantly from $95.4M to $33.0M. The financial picture suggests aggressive cost cutting and debt management have improved operational efficiency despite revenue headwinds, though the cash decline warrants monitoring of liquidity trends.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+77.2%
-$20.2M→-$4.6M

Net income grew 77.2% — bottom-line growth signals improving overall business health.

Total Debt
Balance Sheet
-68.7%
$15.9M→$5.0M

Debt reduced 68.7% — deleveraging strengthens balance sheet and reduces financial risk.

Cash & Equivalents
Balance Sheet
-65.4%
$95.4M→$33.0M

Cash declined 65.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Liabilities
Balance Sheet
-32.8%
$50.6M→$34.0M

Liabilities reduced 32.8% — deleveraging improves balance sheet strength and financial flexibility.

Revenue
P&L
-30.8%
$8.9M→$6.2M

Revenue declined 30.8% — significant demand weakness or market share loss warrants investigation.

Current Liabilities
Balance Sheet
-29.8%
$32.7M→$23.0M

Current liabilities reduced — improved short-term financial position and working capital health.

Gross Profit
P&L
+24%
$50.1M→$62.1M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Accounts Receivable
Balance Sheet
-13.3%
$9.2M→$8.0M

Receivables declined — improved collection efficiency or conservative revenue recognition.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-03-03
ADDED
As of February 19, 2026, 48.3 million shares of the registrant s common stock were outstanding.
FORM 10-K SUMMARY 95 SIGNATURES 96 References throughout this Annual Report on Form 10-K to BioLife Solutions, Inc.
and globally, including but not limited to, disruption in our supply chain, inflation in pricing for key materials or labor, the imposition of trade tariffs or other adverse changes resulting from epidemics, pandemics, and outbreaks of contagious diseases, natural disasters, economic or political instability, terrorist attacks and wars, including the ongoing war in Ukraine, conflict in the Middle East, U.S.
New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.
If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to such updated forward-looking statements or other forward-looking statements.
This Annual Report includes trademarks, tradenames and service marks that are the property of other organizations.
Solely for convenience, trademarks and tradenames referred to in this Annual Report appear without the and symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.
We are dependent on our suppliers and third-party manufacturers, including single-source and sole-source suppliers, and disruptions in our supply chain could adversely affect our ability to manufacture and deliver products.
Our recent divestitures expose us to ongoing risks and uncertainties, one or more of which could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or stock price.
The development, deployment and use of artificial intelligence ("AI") technologies present new risks and challenges that could adversely impact our business Our stock price and volume may be volatile, and purchasers of our securities could incur substantial losses.
REMOVED
As of February 24, 2025, 47.0 million shares of the registrant s common stock were outstanding.
FORM 10-K SUMMARY 97 SIGNATURES 98 References throughout this Form 10-K to BioLife Solutions, Inc.
We intend that such forward-looking statements be subject to the safe harbors for such statements.
You should not place undue reliance on these forward-looking statements, which are subject to significant known and unknown risks, uncertainties and other factors, which are in some cases, beyond our control and which could materially affect results.
If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
We depend on outside suppliers for all our manufacturing supplies, parts and components.
Public health crises have adversely affected, and could in the future adversely affect, our business, financial condition.
We have a diversified portfolio of tools and services that focuses on biopreservation, cell processing, cold chain management tools, and thawing of biologic materials.
The Company is presenting Global Cooling, SciSafe, and CBS within this Annual Report as discontinued operations for all periods presented within the Consolidated Balance Sheets and Consolidated Statements of Operations.
Cell processing Biopreservation media Our proprietary biopreservation media products, HypoThermosol FRS and CryoStor Freeze Media, are formulated to mitigate preservation-induced, delayed-onset cell damage and death which result when cells and tissues are subjected to reduced temperatures.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →